In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Association of amyloid-Beta with arterial stiffness and cardiovascular risk in patients at low cardiovascular risk: a 5-year follow-up study

Session Poster Session 3

Speaker Kateryna Sopova

Event : ESC Congress 2013

  • Topic : basic science
  • Sub-topic : Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis
  • Session type : Poster Session

Authors : K Sopova (Frankfurt am Main,DE), G Georgiopoulos (Athens,GR), D Stakos (Alexandroupolis,GR), G Kollias (Athens,GR), E Efthimiou (Athens,GR), C Papamichael (Athens,GR), K Stellos (Frankfurt am Main,DE), K Stamatelopoulos (Athens,GR)

Authors:
K. Sopova1 , G. Georgiopoulos2 , D. Stakos3 , G. Kollias2 , E. Efthimiou2 , C. Papamichael2 , K. Stellos1 , K. Stamatelopoulos2 , 1Johann Wolfgang Goethe-University Hosp., Department of Medicine, Division of Cardiology - Frankfurt am Main - Germany , 2University of Athens Medical School - Athens - Greece , 3Democritus University of Thrace, Medical School, Department of Cardiology - Alexandroupolis - Greece ,

Citation:
European Heart Journal ( 2013 ) 34 ( Abstract Supplement ), 446

Purpose: Amyloid-β 1-40 (Aβ40) has been associated with vascular inflammation and atherogenesis in experimental studies in vitro and in mice, but no evidence has been reported in humans. The aim of the present study was to determine the possible association of Aβ40 with cardiovascular risk and subclinical atherosclerosis in individuals at low risk for cardiovascular events and without - clinical signs of cardiovascular disease.

Methods: One hundred and twenty-four non-diabetic individuals (age: 47±8.5 years) were consecutively recruited and followed for 5 years. At each visit (baseline and follow-up) detailed risk factor characterization was performed and total cardiovascular risk by Heartscore (HS) was calculated. Moreover, pulse wave velocity (PWV), intima-media thickness (IMT), presence of carotid and femoral plaques, as well as plasma Aβ40 levels were determined at baseline and after 5 years.

Results: Plasma Aβ40 levels associated with increased cardiovascular risk (HS>5% rho=0.221, P=0.017) at baseline and independently predicted (P=0.016) the increase of cardiovascular risk after a 5-year follow-up period (HS before vs. after: 1.55±1.28 versus 2.45±2.22, P<0.001). Moreover, Aβ40 levels were significantly increased after a 5-year follow-up period (26.1±18.5 versus 43.7±25.3, P<0.001). Aβ40 at follow-up independently associated with corresponding PWV (beta=0.182, P=0.009). By linear mixed model analysis, an increase in plasma Aβ40 was associated with HS increase (P=0.033) and concomitant augmentation in PWV (P=0.003) independently of glomerular filtration rate (GFR) and mean blood pressure alteration. No other significant association was observed with other subclinical atherosclerosis surrogate markers in our low-risk cohort.

Conclusions: Elevated plasma levels of Aβ40 over time are associated with the higher rate of cardiovascular risk and arterial stiffness in patients at low cardiovascular risk. Thus, Aβ40 may be critically involved in the early phases of human atherosclerosis. Further prospective studies are required to elucidate the potential role of Aβ40 in subclinical and symptomatic atherosclerosis and its incremental value in patients' risk stratification.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are